Teva Pharmaceutical Industries Limited (TEVA) stock forecast & analysis
41.10
NYSE · USDDelayed by 20 minutes
Up: +1.85, +4.7%
41.22Up: +0.12, +0.3%
1 analysis
Latest analysis: · verdict locked
- Open
- 40.22
- Previous close
- 39.25
- Day range
- 40.12 – 42.02
- 52-week range
- 18.83 – 42.02
- Volume (shares)
- 14.36M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 1.17B
- P/E ratio
- 68.50
- Dividend yield
- 0.00%
- Beta
- 0.82
- Market cap
- 47.93B
Market Scanner’s AI analysis of Teva Pharmaceutical Industries Limited (TEVA), updated October 2026: Teva's stock shows upward momentum driven by FDA approval for schizophrenia treatment, alongside mixed financial performance.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Teva Pharmaceutical Industries Limited (TEVA) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Teva's stock shows upward momentum driven by FDA approval for schizophrenia treatment, alongside mixed financial performance.
Recent analyses covered Teva Pharmaceutical Industries Limited (TEVA), noting its stock's upward momentum with positive short-term and long-term trends indicated by moving averages and RSI. The company's financial performance showed a slight year-over-year revenue decrease and a quarterly net loss, contrasting with a full-year net income in 2025. A key catalyst discussed was the FDA approval for a monthly schizophrenia shot, contributing to a year-to-date stock surge.
TEVA news & sentiment
News reports highlighted significant positive momentum for Teva Pharmaceutical Industries, driven by a notable stock surge and FDA approval for a new treatment. Social media discussions were not covered in the provided notes.
TEVA technical picture
TEVA's stock price demonstrated upward momentum, trading above its 50-day and 200-day simple moving averages. Momentum indicators such as the 7-day, 30-day, and 91-day price changes, along with the MACD, showed positive trends. The RSI approached overbought levels, while the MFI indicated neutral to slightly positive money flow, and the price was trading above the upper Bollinger Band.
Fundamentals
Teva's recent revenue showed a year-over-year decrease, and the company reported a quarterly net loss, though it achieved full-year net income in the prior year. The analysis covered profitability metrics including profit and operating margins, alongside return on equity.
Factors discussed — upside
- Stock trading above 50-day and 200-day SMAs, indicating positive medium and long-term trends.
- Positive short-term momentum indicated by 7-day, 30-day, and 91-day price changes.
- FDA approval for a monthly schizophrenia shot, leading to a 52-week high.
- Positive MACD indicating bullish momentum.
- Strong buying pressure indicated by RSI approaching overbought territory.
Factors discussed — risks
- Quarterly revenue showed a year-over-year decrease of 0.8%.
- Reported a net loss of $576 million for the latest reported quarter.
- Stock price trading above the upper Bollinger Band, suggesting potential short-term overextension.
- Technical indicators
- Financial performance
- Regulatory approvals
- Market sentiment
Summary updated .
TEVA technical indicators
Common technical indicators for TEVA, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 37.62 | Price above |
| 10-day exponential moving average | 39.62 | Price above |
| Relative strength index (14-day) | 65.32 | Neutral |
| MACD line (12/26/9) | 0.7042 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 38.28 – 40.54 | Price above the upper band |
Analyses
Recent TEVA.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-11 TEVA.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Teva Pharmaceutical Industries Limited?
- The bull case for TEVA centers on its stock exhibiting positive medium and long-term trends, supported by strong buying pressure and bullish momentum. A significant catalyst is the FDA approval for a monthly schizophrenia shot, which propelled the stock to a 52-week high.
- What are the risks for Teva Pharmaceutical Industries Limited?
- Risks for TEVA include a slight year-over-year decrease in quarterly revenue and a net loss reported for the most recent quarter. Additionally, the stock price trading above the upper Bollinger Band suggests potential short-term overextension.
- Is Teva Pharmaceutical Industries Limited bullish or bearish?
- Recent AI analyses of Teva Pharmaceutical Industries Limited examined factors on both sides. Discussed upside: The bull case for TEVA centers on its stock exhibiting positive medium and long-term trends, supported by strong buying pressure and bullish momentum. A significant catalyst is the FDA approval for a monthly schizophrenia shot, which propelled the stock to a 52-week high. Discussed risks: Risks for TEVA include a slight year-over-year decrease in quarterly revenue and a net loss reported for the most recent quarter. Additionally, the stock price trading above the upper Bollinger Band suggests potential short-term overextension. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Teva Pharmaceutical Industries Limited?
- News reports highlighted significant positive momentum for Teva Pharmaceutical Industries, driven by a notable stock surge and FDA approval for a new treatment. Social media discussions were not covered in the provided notes.
- How does Market Scanner analyse Teva Pharmaceutical Industries Limited?
- Every analysis of Teva Pharmaceutical Industries Limited runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Teva Pharmaceutical Industries Limited?
The bull case for TEVA centers on its stock exhibiting positive medium and long-term trends, supported by strong buying pressure and bullish momentum. A significant catalyst is the FDA approval for a monthly schizophrenia shot, which propelled the stock to a 52-week high.
What are the risks for Teva Pharmaceutical Industries Limited?
Risks for TEVA include a slight year-over-year decrease in quarterly revenue and a net loss reported for the most recent quarter. Additionally, the stock price trading above the upper Bollinger Band suggests potential short-term overextension.
Is Teva Pharmaceutical Industries Limited bullish or bearish?
Recent AI analyses of Teva Pharmaceutical Industries Limited examined factors on both sides. Discussed upside: The bull case for TEVA centers on its stock exhibiting positive medium and long-term trends, supported by strong buying pressure and bullish momentum. A significant catalyst is the FDA approval for a monthly schizophrenia shot, which propelled the stock to a 52-week high. Discussed risks: Risks for TEVA include a slight year-over-year decrease in quarterly revenue and a net loss reported for the most recent quarter. Additionally, the stock price trading above the upper Bollinger Band suggests potential short-term overextension. These are descriptive observations, not a recommendation.
What is the latest sentiment on Teva Pharmaceutical Industries Limited?
News reports highlighted significant positive momentum for Teva Pharmaceutical Industries, driven by a notable stock surge and FDA approval for a new treatment. Social media discussions were not covered in the provided notes.
How does Market Scanner analyse Teva Pharmaceutical Industries Limited?
Every analysis of Teva Pharmaceutical Industries Limited runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh TEVA.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.